MOUNTAIN VIEW, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Omnicell, Inc. , a leading provider of patient safety solutions preferred by nurses, today announced third quarter 2005 results.
Omnicell Chairman, President and CEO Randall A. Lipps commented, “I’m delighted with the progress our company has made over the last six months. We’ve built our backlog quicker than anticipated, and we’ve achieved some great wins in the marketplace recently. Our focus on linearity throughout the quarter is greatly benefiting our cost structure, predictability, and customer satisfaction. We feel we’re very well positioned moving into the fourth quarter of this year and fiscal 2006. Our singular focus on automation solutions and the quality of our products and services are resonating with our customers -- especially integrated delivery networks -- and are differentiating us from our competitors.”
During Q3 2005, Omnicell added $8.2 million to product backlog, bringing backlog to a record $62.1 million, a 32% increase from year-end 2004 and up 15% sequentially. This has enabled the company to achieve its stated backlog objective for entering 2006 one quarter ahead of schedule.
Revenue for the third quarter of 2005 totaled $30.7 million, down 6% from the third quarter of 2004, but up 7% sequentially from Q2 2005. The company has made a conscious decision to increase its backlog during 2005 to improve customer satisfaction, predictability of results, and efficient management of its business within the quarter and across multiple quarters. The growth in backlog equates to about 12 percentage points of revenue growth on a year-to-date basis that has been banked to achieve these goals. The company is focused on operating at the customer’s pace and maximizing the customer experience in working with Omnicell.
These changes have benefited gross margin, which continued to show improvement to 58.3% in Q3 2005, up 1.4 points from Q2 2005 and consistent with Q3 2004 on a lower revenue base. Gross margin is now back in line with the percentage realized during fiscal 2003 and 2004. During the quarter, the company’s operating expense structure benefited from improved linearity as well. During Q3 2005, operating expenses totaled $16.6 million, up $0.3 million from Q2 2005 and up $0.8 million from Q3 2004. The increase from Q2 2005 was primarily driven by variable costs tied to revenues.
Net income improved during the quarter from a profit of $66,000 ($0.00 EPS) in Q2 2005 to $1.4 million ($0.05 EPS) in Q3 2005. The improvement in net income was achieved on an increase of $2.1 million of revenue and was primarily due to the increase in gross margin.
Interim CFO, James T. Judson added, “We’re very pleased with the strength we’ve seen in orders the past two quarters. It has enabled us to build our backlog and position the company to operate much more efficiently. It’s also allowing us to shift our focus to improving the customer experience. Our company has an excellent reputation for product quality and service. We feel that raising the bar on the customer experience will enable us to maximize the market opportunity we see in front of us.”
Financial Results Conference Call Details
Management will discuss financial results for the third quarter of 2005 on Thursday, Oct. 20, 2005 at 1:30 p.m. PT via conference call. Investors and analysts may listen to this conference call by logging on to www.omnicell.com or by dialing 800-257-1927 (domestic) or 303-205-0066 (international) approximately 10 minutes prior to the scheduled start. A replay of the call will be available from 3:30 p.m. PT on Oct. 20, 2005 through 11:59 p.m. PT on Oct. 27, 2005. Dialing 800-405-2236 (domestic) or 303-590-3000 (international) and entering the passcode 11041318# for both numbers will access the call replay. On the conference call, management will be discussing certain additional financial and statistical information. That information can be located on the “Investor Relations” page of Omnicell’s Web site at www.omnicell.com.
About Omnicell
Established in 1992, Omnicell is a leading provider of patient safety solutions preferred by nurses. Improving patient care by enhancing operational efficiency, Omnicell solutions are used throughout the healthcare facility -- in the pharmacy, nursing units, surgical services, cath lab, and all the way to the patient’s bedside. The company’s MedGuard(TM) line of solutions for the medication-use process includes systems for physician order management, automated pharmacy retrieval, medication packaging, medication dispensing, and nursing workflow automation with bar code medication administration. For the medical-surgical supply chain, Omnicell provides open bar code systems, cabinet-based supply management, integrated open and cabinet-based systems, and Web-based procurement. More than 1,600 healthcare facilities use Omnicell solutions to help reduce medication errors, operate more efficiently, and decrease costs -- ultimately contributing to improved clinical and financial outcomes. For more information, visit www.omnicell.com.
Forward-Looking Statements
To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell’s control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the Company’s Securities and Exchange Commission filings and include, without limitation, the continued growth and acceptance of our products and services and the continued growth of the clinical automation and workflow automation market generally, the potential of increasing competition, the ability of the company to maintain its profitability, grow product backlog, retain key personnel, cut expenses, develop new products and integrate acquired products or intellectual property in a timely and cost-effective manner, and improve sales productivity. Prospective investors are cautioned not to place undue reliance on forward-looking statements.
OMNICELL, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (Unaudited) Three months Change Nine months Change ended (%) ended (%) September 30, September 30, 2005 2004 2005 2004 Revenues: Product revenues $24,194 $26,767 $68,688 $72,374 Service and other revenues 6,494 5,967 19,349 17,396 Total revenues 30,688 32,734 -6% 88,037 89,770 -2% Costs of revenues: Cost of product revenues 10,572 11,344 32,157 29,881 Cost of service and other revenues 2,226 2,302 7,349 6,508 Total cost of revenues 12,798 13,646 39,506 36,389 Gross profit 17,890 19,088 -6% 48,531 53,381 -9% Operating expenses: Research and development 2,143 2,476 7,584 6,679 Selling general and administrative 14,446 13,325 45,152 38,419 Restructuring and severance charges -- -- 406 171 Total operating expenses 16,589 15,801 5% 53,142 45,269 17% Income from operations 1,301 3,287 (4,611) 8,112 Interest and other income 156 105 404 266 Interest and other expense (6) (12) (35) (70) Income before provision for income taxes 1,451 3,380 (4,242) 8,308 Provision for income taxes 36 124 69 325 Net income $1,415 $3,256 -57% $(4,311) $7,983 -154% Net income per share - basic $0.05 $0.13 $(0.17) $0.32 Net income per share - diluted $0.05 $0.12 $(0.17) $0.29 Weighted average shares outstanding - basic 26,101 25,038 4% 25,792 24,697 4% Weighted average shares outstanding - diluted 27,297 27,571 -1% 25,792 27,809 -7% OMNICELL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) September December 30, 31, Change 2005 2004 (1) ($) (%) (Unaudited) ASSETS Current assets: Cash & cash equivalents $29,500 $19,482 10,018 51% Short-term investment 2,008 11,117 (9,109) -82% Accounts receivable, net 30,204 21,967 8,237 37% Inventories 14,934 14,592 342 2% Receivables subject to a sales agreement 2,987 2,878 109 4% Other current assets 8,438 7,730 708 9% Total current assets 88,071 77,766 10,305 13% Property and equipment, net 4,994 5,660 (666) -12% Long-term receivables subject to a sales agreement 1,651 3,224 (1,573) -49% Other assets 8,939 12,841 (3,902) -30% Total assets $103,655 $99,491 4,164 4% LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $4,989 $4,489 500 11% Accrued liabilities 12,215 12,918 (703) -5% Deferred service revenue 16,625 13,922 2,703 19% Deferred gross profit 12,179 7,846 4,333 55% Obligation resulting from sale of receivables 2,987 2,878 109 4% Total current liabilities 48,995 42,053 6,942 17% Long-term obligation resulting from sale of receivables 1,651 3,224 (1,573) -49% Other long-term liabilities 250 517 (267) -52% Stockholders’ equity 52,759 53,697 (938) -2% Total liabilities and stockholders’ equity $103,655 $99,491 4,164 4% (1) Derived from the December 31, 2004 audited consolidated balance sheet.
Omnicell, Inc.
CONTACT: James T. Judson, Vice President of Finance and Interim CFO ofOmnicell, 800-850-6664, ext. 6118, or jimj@omnicell.com
Web site: http://www.omnicell.com//
